AMEERA-3 | ACT16105
NCT04059484
JCP067
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)
Status:
Closed to Accrual
II
Phase
2nd
Line of Therapy
Advanced / Metastatic
Disease Stage
Biomarker(s)
ER+, HER2-
Investigational
Product
SAR439859
Selective Estrogen Degrader (SERD), p.o.
Treatment Arms
SAR439859 vs Control treatment of the choice of the physician (1:1):
o Fulvestrant
o Aromatase inhibitors (anastrozole, letrozole, exemestane)
o Selective estrogen receptor modulator (Tamoxifen)